Redox
Total Raised
$98MInvestors Count
17Deal Terms
2Funding, Valuation & Revenue
13 Fundings
Redox has raised $98M over 13 rounds.
Redox's latest funding round was a Series D for $45M on February 24, 2021.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
2/24/2021 | Series D | $45M | 14 | |||
5/7/2019 | Series C - II | $3.1M | 1 | |||
4/17/2019 | Series C | $33M | 4 | |||
8/31/2018 | Debt | |||||
4/6/2017 | Series B - II |
Date | 2/24/2021 | 5/7/2019 | 4/17/2019 | 8/31/2018 | 4/6/2017 |
|---|---|---|---|---|---|
Round | Series D | Series C - II | Series C | Debt | Series B - II |
Amount | $45M | $3.1M | $33M | ||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 14 | 1 | 4 |
Redox Deal Terms
2 Deal Terms
Redox's deal structure is available for 2 funding rounds, including their Series B from January 24, 2017.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Redox Investors
17 Investors
Redox has 17 investors. .406 Ventures invested in Redox's Series D funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/20/2015 | 2/24/2021 | 5 Series A, Series B (2017), Series C (2019), Series C - II (2019), Series D (2021) | Venture Capital | Massachusetts | ||
1/24/2017 | 2/24/2021 | 4 Series B, Series C (2019), Series C - II (2019), Series D (2021) | Venture Capital | New York | ||
4/17/2019 | 2/24/2021 | 3 Series C, Series C - II (2019), Series D (2021) | Venture Capital | Massachusetts | ||
Venture Capital | New York | |||||
Private Equity | Illinois |
First funding | 10/20/2015 | 1/24/2017 | 4/17/2019 | ||
|---|---|---|---|---|---|
Last Funding | 2/24/2021 | 2/24/2021 | 2/24/2021 | ||
Investor | |||||
Rounds | 5 Series A, Series B (2017), Series C (2019), Series C - II (2019), Series D (2021) | 4 Series B, Series C (2019), Series C - II (2019), Series D (2021) | 3 Series C, Series C - II (2019), Series D (2021) | ||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Venture Capital | Private Equity |
Location | Massachusetts | New York | Massachusetts | New York | Illinois |
Compare Redox to Competitors
Rhapsody focuses on digital health enablement in the healthcare sector. It offers interoperability solutions that integrate and manage health data, providing services such as data integration, terminology management, and education services. Rhapsody Health was formerly known as Lyniate. The company was founded in 1997 and is based in Boston, Massachusetts.
eClinicalWorks focuses on electronic health records (EHR) and practice management. The company provides products including telehealth services, population health management, patient engagement, and revenue cycle management. eClinicalWorks serves the healthcare sector, providing solutions for various medical specialties. It was founded in 1999 and is based in Westborough, Massachusetts.
ELLKAY specializes in healthcare data management and operates within the healthcare technology sector. The company offers cloud-based solutions for data exchange and workflow management. ELLKAY serves various clients, including hospitals, health systems, laboratories, healthcare information technology (IT) vendors, payers, and ambulatory practices. It was founded in 2002 and is based in Elmwood Park, New Jersey.
Health Gorilla focuses on health information exchange and interoperability solutions. The company offers products such as electronic health record data access and lab data automation, aimed at improving data connectivity within the healthcare ecosystem. Health Gorilla serves sectors including digital health, electronic health records, health information exchanges, lab vendors, payers, providers, and life insurance. It was founded in 2014 and is based in Miami, Florida.
1upHealth specializes in health data management and interoperability within the healthcare industry. The company offers a Fast Healthcare Interoperability Resources (FHIR)-enabled platform that facilitates claims and clinical data acquisition, exchange, and analysis to meet regulatory requirements. 1upHealth serves clients, including payers, providers, digital health organizations, and life sciences companies. It was founded in 2017 and is based in Boston, Massachusetts.
Particle Health specializes in healthcare data interoperability and analytics within the healthcare industry. The company offers a clinical platform that gives access to patient medical records and synthesizes clinical insights to support various healthcare needs. The company provides services to payers and developers seeking to utilize healthcare data. It was founded in 2018 and is based in New York, New York.
Loading...